Age: 72.0
Sex: M
Vaccine: COVID19, UNK
Symptoms: Blood glucose, Burning sensation, Dermatitis atopic, Erythema, Eye irritation
Clinical narrative: consumer's eyes, shoulders, arms, calves, and between his fingers are itchy/still has a raw, red, flaky, and itchy skin; his calves are red and the back of his hands are red/still has a raw, red, flaky, and itchy skin; left eye fogginess; after receiving the Moderna vaccine experienced burning in the right leg which started from his hip to his foot; eyes are flaky/ both of his eyes crusted over with burning; both of his eyes crusted over with burning; both of his eyes are itchy and raw; oozing open wounds; oozing open wounds; still has a raw, red, flaky, and itchy skin; eyes flare up twice a day/flare up of his AD crotch, back of hands, between his fingers, stomach, arms, shoulders and calves; eyes flare up twice a day/flare up of his AD crotch, back of hands, between his fingers, stomach, arms, shoulders and calves; eye sores; sores appeared back on his eye lids; consumer's shoulders, arms, calves, and between his fingers are flaky, and itchy skin; took his dose and felt a sharp pain when the needle went in, he thinks he might have hit something in his body; This spontaneous case was reported by a patient and describes the occurrence of WOUND (oozing open wounds), WOUND SECRETION (oozing open wounds), SKIN EROSION (still has a raw, red, flaky, and itchy skin), EYE ULCER (eye sores) and ULCER (sores appeared back on his eye lids) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product DUPILUMAB (DUPIXENT) for Atopic dermatitis.    The patient's past medical history included Back injury, Bladder discomfort, Prostatic disorder and Spinal operation.   On 03-Nov-2020, the patient started DUPILUMAB (DUPIXENT) (Subcutaneous) 300. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Jan-2021, the patient experienced INJECTION SITE PAIN (took his dose and felt a sharp pain when the needle went in, he thinks he might have hit something in his body). On 23-Feb-2021, the patient experienced SKIN EXFOLIATION (consumer's shoulders, arms, calves, and between his fingers are flaky, and itchy skin). In March 2021, the patient experienced ULCER (sores appeared back on his eye lids). On 16-Apr-2021, the patient experienced EYE ULCER (eye sores). On an unknown date, the patient experienced WOUND (oozing open wounds), WOUND SECRETION (oozing open wounds), SKIN EROSION (still has a raw, red, flaky, and itchy skin), DERMATITIS ATOPIC (eyes flare up twice a day/flare up of his AD crotch, back of hands, between his fingers, stomach, arms, shoulders and calves), THERAPEUTIC RESPONSE DECREASED (eyes flare up twice a day/flare up of his AD crotch, back of hands, between his fingers, stomach, arms, shoulders and calves), PRURITUS (consumer's eyes, shoulders, arms, calves, and between his fingers are itchy/still has a raw, red, flaky, and itchy skin), ERYTHEMA (his calves are red and the back of his hands are red/still has a raw, red, flaky, and itchy skin), VISION BLURRED (left eye fogginess), BURNING SENSATION (after receiving the Moderna vaccine experienced burning in the right leg which started from his hip to his foot), EYELID MARGIN CRUSTING (eyes are flaky/ both of his eyes crusted over with burning), EYE IRRITATION (both of his eyes crusted over with burning) and EYE PRURITUS (both of his eyes are itchy and raw). The patient was treated with MYCOPHENOLATE MOFETIL (MYCOPHENOLATE) in March 2021 for Eye ulcer, at an unspecified dose and frequency; TRIAMCINOLONE for Eye pruritus, at an unspecified dose and frequency and COAL TAR for Eye irritation, at an unspecified dose and frequency. At the time of the report, WOUND (oozing open wounds), WOUND SECRETION (oozing open wounds), SKIN EROSION (still has a raw, red, flaky, and itchy skin), EYE ULCER (eye sores), ULCER (sores appeared back on his eye lids), BURNING SENSATION (after receiving the Moderna vaccine experienced burning in the right leg which started from his hip to his foot), EYELID MARGIN CRUSTING (eyes are flaky/ both of his eyes crusted over with burning) and EYE IRRITATION (both of his eyes crusted over with burning) was resolving, DERMATITIS ATOPIC (eyes flare up twice a day/flare up of his AD crotch, back of hands, between his fingers, stomach, arms, shoulders and calves), SKIN EXFOLIATION (consumer's shoulders, arms, calves, and between his fingers are flaky, and itchy skin), PRURITUS (consumer's eyes, shoulders, arms, calves, and between his fingers are itchy/still has a raw, red, flaky, and itchy skin), ERYTHEMA (his calves are red and the back of his hands are red/still has a raw, red, flaky, and itchy skin), VISION BLURRED (left eye fogginess) and EYE PRURITUS (both of his eyes are itchy and raw) had not resolved, THERAPEUTIC RESPONSE DECREASED (eyes flare up twice a day/flare up of his AD crotch, back of hands, between his fingers, stomach, arms, shoulders and calves) outcome was unknown and INJECTION SITE PAIN (took his dose and felt a sharp pain when the needle went in, he thinks he might have hit something in his body) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 25-May-2021, Blood glucose: increased (Inconclusive) Increased.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No other concomitants were reported.  Company Comment: Very limited information regarding this event has been provided at this time. Exact date of administration of vaccine and onset date for the events are required for further evaluation. However, noting the history of atopic dermatitis may remain as risk factor and  concurrent treatment with dupilumab may remain as a co-suspect.; Sender's Comments: Very limited information regarding this event has been provided at this time. Exact date of administration of vaccine and onset date for the events are required for further evaluation. However, noting the history of atopic dermatitis may remain as risk factor and  concurrent treatment with dupilumab may remain as a co-suspect.